Analysts/Institutional Investor Meet/Con. Call Updates

August 06, 2026 BSE Limited, National Stock Exchange of India Limited, P J Towers, Exchange Plaza, Dalal Street, Bandra-Kurla Complex, Bandra, Mumbai - 400 001. Mumbai - 400 051. Scrip Code: 524735 Symbol: HIKAL Dear Sir/Madam, Subject: Results Presentation of the Company for the quarter ended June 30, 2026 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of the Results presentation on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. This is for your information and records. Thank you, Yours Sincerely, For Hikal Limited, Rajasekhar Reddy Company Secretary & Compliance Officer Encl: As above Hikal Ltd. Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91–22–6277 0299, + 91–22–6866 0300 Regd. Office: 717/718, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500 www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028 Investor Presentation Q1 FY27 August 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Leading with Q1 FY27 was a slower start to the beginning of the year as we transition from regulatory-led disruption to growth. Vision We delivered Revenue of ₹403 Cr. with an EBITDA margin of 9.2%. Mr. Jai Hiremath, In our Pharmaceutical Business we are in the penultimate stage of our remediation plan with the US FDA. A Executive Chairman significant amount of time and resources have been invested to ensure the highest level of compliance. The remediation plan has slowed down sales in our Pharma business as we have taken additional time in our plant shutdowns based on recommendations by global regulatory authorities as well as some of our consultants. We are confident on capitalising on our CDMO pipeline and specialty APIs, Oncology, CNS, Gastroenterology and complex chemistries. Continued investments in High Potency capabilities and accelerated DMF filings will further strengthen our long-term competitive position. Our Crop Protection business witnessed improved domestic demand in the Own Products segment supported by higher volumes, while CDMO demand remained subdued due to ongoing inventory adjustments at our customer’s end. In addition, geopolitical developments led to a significant rise across all input costs including raw materials, resulting in margin pressure. We expect a sequential improvement going forward. Our Animal Health business continued to deliver resilient performance, supported by stronger customer partnerships, commercialization of new programs and an expanding development pipeline comprising of multiple advanced intermediates and NCEs. Our Personal Care business achieved an important milestone with the commissioning of the dedicated Panoli manufacturing facility. We remain focused on customer approvals, expanding our UV filter skincare portfolio and strengthening partnerships with leading global and domestic personal care companies to capitalize on growing demand for specialty ingredients. As part of our long-term strategy and commitment to sustainability, I am pleased to inform you that we have received the Gold rating from EcoVadis placing ourselves in the top 5% of companies globally. Looking ahead, we remain confident in a stepwise recovery of revenues and profitability during this year. 3 Q1FY27: Performance at a Glance Q1FY27: Consolidated Performance Summary CONSOLIDATED: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q4FY26 Q1FY26 Q1FY27 Revenue grew 6.2% despite geopolitical and macroeconomic headwinds, Revenue 519 380 403 supported by improving customer demand and execution EBITDA 105 25 37 Quarterly EBITDA of ₹37 crores, growth of 47.4% YoY with margins of EBITDA% 20.3% 6.6% 9.2% 9.2%, +260 bps PBT before 55 (30) (19) exceptional items Pharmaceutical business continued its recovery with improving Exceptional customer offtake with 58% share across Own Products and CDMO, 47 0 (9) expense/(income) supported by strengthening regulated market demand. PBT after 8 (30) (14) exceptional items Crop Protection business delivered volume-led growth in Own Products, PAT 14 (22) (7) while CDMO remained impacted by customer inventory adjustments and higher input costs. EPS 1.17 (1.82) (0.6) 100+ customer audits passed at Bangalore facility. CONSOLIDATED: REVENUE SPLIT% Business momentum is expected to strengthen progressively through In % Q4FY26 Q1FY26 Q1FY27 FY27, supported by improving demand visibility, expanding CDMO Pharmaceuticals 56% 53% 58% opportunities and continued focus on operational excellence. Crop-Protection 44% 47% 42% Q1FY27: Pharmaceuticals Performance Summary PHARMACEUTICALS: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q4FY26 Q1FY26 Q1FY27 Pharmaceutical business delivered revenue of ₹233 Cr in Q1FY27, growth of 15.2% YoY Revenue 292 203 233 Continued portfolio expansion across differentiated APIs and specialty EBIT 35 (26) 8 therapies including Oncology, CNS, Gastroenterology and Anti-diabetics. Strengthened presence across regulated and emerging markets with PHARMACEUTICALS: REVENUE SPLIT% increasing focus on Japan, LATAM, MENA and other strategic geographies In % Q4FY26 Q1FY26 Q1FY27 DMF filing trajectory increasing to 5–6 filings annually versus 2–3 CDMO 55% 49% 59% historically Own Products 45% 51% 41% Molecule mix continues to shift towards higher-value final APIs Co [Showing first 8,000 characters — download PDF for full document]